Bleomycin
- Generic Name
- Bleomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C55H84N17O21S3
- CAS Number
- 11056-06-7
- Unique Ingredient Identifier
- 40S1VHN69B
- Background
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
- Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
- Associated Conditions
- Hodgkin's Lymphoma, Malignant Pleural Effusion, Non-Hodgkin's Lymphomas, Squamous Cell Carcinoma (SCC), Teratocarcinoma, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma
- Associated Therapies
- Palliative Treatment
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 402
- Registration Number
- NCT03018626
- Locations
- 🇨🇳
Ru Feng, Guangzhou, Guangdong, China
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02784054
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02782754
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
HD21 for Advanced Stages
- Conditions
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1500
- Registration Number
- NCT02661503
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
Electrochemotherapy on Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 25
- Registration Number
- NCT02549742
- Locations
- 🇩🇰
Department of Otorhinolaryngology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Beihua Kong
- Target Recruit Count
- 129
- Registration Number
- NCT02429687
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Beihua Kong
- Target Recruit Count
- 132
- Registration Number
- NCT02429700
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 40
- Registration Number
- NCT02298283
- Locations
- 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷Hôpital André Mignot, Le Chesnay, France
🇫🇷Centre Léon Bérard, Lyon, France
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 170
- Registration Number
- NCT02292979
- Locations
- 🇳🇱
Reinier De Graaf Gasthuis, Delft, Netherlands
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇫🇷CHU de Clermont-Ferrand, Clermont-Ferrand, France
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
- Conditions
- Interventions
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.